Skip to Content

Gene Therapy on the Mend as Treatment Gets Western Approval

Regulatory approval of a gene therapy treatment in Europe could spark broader patient access to the technology.

Last month, Europe’s Committee for Medicinal Products for Human Use approved a gene therapy for a rare genetic disease, the first time a Western regulatory agency has okayed such a treatment, though gene therapies have been approved in China.

Gearing up: A technician installs a piece of lab equipment that will grab viruses out of their growth medium in UniQure’s manufacturing facility in Amsterdam.

The virus-mediated treatment, called Glybera, which is being developed by Amsterdam-based UniQure, introduces a normal version of a gene needed to properly break down fats in the blood. Though the condition is rare, patients with dysfunctional copies of this gene have dramatically increased levels of fat in their blood, which can lead to fatal inflammation of the pancreas. The genetic repair lowers blood fat concentration and reduces the frequency of pancreatitis, according to clinical trial data.

The approval is just another sign that the field of gene therapy is quietly enjoying a resurgence after disastrous results in the late 1990s derailed testing of the technology. A number of companies are now testing various gene therapy products. For example, in 2010, Cambridge, Massachusetts-based Bluebird Bio reported it had successfully treated an 18-year-old patient for a rare blood disease (see “Gene Therapy Combats Hereditary Blood Disease”). Hemophilia, immune deficiencies, and blindness have all been treated with at least some benefit to the patients willing to try the experimental therapy. And large pharmaceutical companies such as Novartis, GlaxoSmithKline, and Baxter have taken on gene therapy projects in recent years.

Trailblazing therapy: Glybera, which treats a rare fat-processing disorder, is the first gene therapy product approved outside of China.

“The fact that there were no approved gene therapy drugs up until recently probably made a subliminal impression on people that it wasn’t ready for prime time,” says Jean Bennett, a physician-scientist at the University and Pennsylvania and Perelman School of Medicine in Philadelphia. Bennett is involved in a clinical trial of gene therapy for an inherited form of blindness. “Now that there is one approved gene therapy product in the Western world, there is hope that there will be many others.”

Indeed, recent positive results have helped push the field beyond its early setbacks, perhaps the most public of which was the death of 18-year-old Jesse Gelsinger, who died in 1999 after receiving an experimental gene therapy for a genetic condition (see “A Death in Philadelphia”).  Other early gene therapy patients had severe or even deadly immune reactions.  Some patients who received gene therapy injections got cancer as a result of the treatment (see “The Glimmering Promise of Gene Therapy”). These setbacks raised the question of whether the treatment could be done safely.

The basic concept of gene therapy—replacing a defective gene or adding in a functional copy— is straightforward, but the trick is in the delivery. Gene therapies are often carried into a patient’s cells by viruses. Some of the early problems with the therapies were due to strong immune reaction to the transport viruses or cancer sparked by genomic changes induced by the viruses. But in recent years, researchers have found safer viruses and techniques for getting the replacement genes into a patient’s body.

 “The promise of gene therapy is phenomenal—a one-time treatment that will restore the natural function of the body,” says Jörn Aldag, CEO of UniQure. “Many people have pushed back and said it would never be approved, but now we are over the hump,” says Aldag.

UniQure has already built a manufacturing facility capable of commercial-scale production. Aldag expects Glybera to go on sale in the third quarter of 2013. In the meantime, the company must figure out what to charge for the treatment. The company is mulling the fact that treatments for other metabolic diseases can cost $200,000 per year or more, and that Glybera may be needed only once in a patient’s lifetime, says Aldag.  “How do you price a one-off treatment?”

Keep Reading

Most Popular

This new data poisoning tool lets artists fight back against generative AI

The tool, called Nightshade, messes up training data in ways that could cause serious damage to image-generating AI models. 

Rogue superintelligence and merging with machines: Inside the mind of OpenAI’s chief scientist

An exclusive conversation with Ilya Sutskever on his fears for the future of AI and why they’ve made him change the focus of his life’s work.

The Biggest Questions: What is death?

New neuroscience is challenging our understanding of the dying process—bringing opportunities for the living.

Driving companywide efficiencies with AI

Advanced AI and ML capabilities revolutionize how administrative and operations tasks are done.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.